Global Heart Failure Drugs Market, By Type (ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blocker, Diuretics, Others), Application (Injection, Capsule, Tablets), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Specialty Centres, Others) - Industry Trends and Forecast to 2030.
Heart Failure Drugs Market Analysis and Size
The increase in the rate of cardiovascular cases among people and the growing geriatric population globally are the major factors driving the heart failure drugs market. The increase in the need for these drugs as they treat different symptoms of the disorder and the patient's dependency on them accelerates the growth of heart failure drugs. The change in lifestyle, such as excessive alcohol consumption, smoking, and unhealthy diet habits, causes heart problems propelling the heart failure drugs market. The increase in investment by key players and the increase in research and development activities influence the heart failure drugs market. Additionally, increased heart problems due to obesity and lack of physical activities boost the heart failure drugs market. Furthermore, the rise in demand for effective drugs and treatment and product approval extends profitable opportunities to the market of heart failure drugs.
However, the side effects of consuming these drugs are expected to obstruct the heart failure drug market growth. Rising concerns regarding increasing contractility may damage the myocardium and shorten the survival of these patients is projected to challenge the heart failure drugs market.
Data Bridge Market Research analyses that the heart failure drugs market which was USD 8,010.62 million in 2023, would rocket up to USD 24,919.55 million by 2030, and is expected to undergo a CAGR of 15.56% during the forecast period. This indicates that the market value. "Beta blockers" dominates the type segment of the heart failure drugs market due to increasing awareness about heart failure drugs. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Heart Failure Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Type (ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, Others), Application (Injection, Capsule, Tablets), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), End Users (Hospitals, Specialty Centres, Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Amgen Inc. (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Novartis AG (Switzerland), Gilead Sciences, Inc (U.S.), GlaxoSmithKline plc (U.K.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd (Israel), Cardurion Pharmaceuticals (U.S.), Cardior Pharmaceuticals (Germany), Actelion Pharmaceuticals Ltd (Switzerland), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (U.S.), CYTOKINETICS, INC. (U.S.), and Eli Lilly and Company (U.S.) among others.
|
|
Market Opportunities
|
|
Market Definition
The heart failure drugs market refers to the global pharmaceutical industry segment that encompasses developing, producing, and commercializing medications specifically designed to treat heart failure. Heart failure is a chronic medical condition characterized by the heart's inability to pump enough blood to meet the body's demands. This market focuses on drugs that aim to alleviate symptoms, improve heart function, and enhance patients' quality of life.
Heart failure drugs include a range of therapeutic agents targeting different aspects of the condition, such as reducing fluid build-up, managing blood pressure, improving cardiac contractility, and addressing underlying causes. These medications can include diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, aldosterone antagonists, and others.
Heart Failure Drugs Market Dynamics
Drivers
- Increasing Prevalence of Heart Failure
The global prevalence of heart failure is rising due to an aging population, sedentary lifestyles, unhealthy dietary habits, and increased risk factors like obesity, diabetes, and hypertension. This growing patient population fuels the demand for effective heart failure drugs.
- Rising Awareness and Early Diagnosis
Increasing awareness about heart failure symptoms, risk factors, and the importance of early diagnosis has resulted in more patients seeking medical help at an earlier stage. Timely diagnosis enables prompt initiation of treatment, leading to a greater demand for heart failure drugs.
- Growing Healthcare Expenditure
Rising healthcare expenditure globally, especially in developed economies, increases access to healthcare services and medications. Governments and private insurers often cover a significant portion of the costs associated with heart failure drugs, making them more accessible to patients.
Opportunities
- Technological Advancements and Medical Innovations
Medical research and technological advances have led to development of novel therapeutic approaches and drug formulations for heart failure treatment. These innovations include introducing new drug classes, improved drug delivery systems, and targeted therapies, enhancing the effectiveness and safety of heart failure drugs.
Restraint/Challenge
- High Development Costs
The research, development, and clinical trial costs of bringing a heart failure drug to market can be substantial. The extensive investment required and the risk of failure during the development process can deter some pharmaceutical companies from pursuing research in this field. High development costs may limit the number of new drugs entering the market and potentially slow innovation.
This heart failure drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Heart failure drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In September 2022, Bayer launched a novel heart failure drug in India that it has co-developed with Merck at one-fifteenth of the global price at Rs 127 per pill. It's a one-pill-a-day therapy. Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalization among worsening heart failure patients.
Global Heart Failure Drugs Market Scope
The heart failure drugs market is segmented on the basis of type, application, distribution channel, and end users. The growth amongst these segments will help you meagre growth segments in the industries and provide the users with a valuable market overview and insights to help them make strategic decisions for identifying core market applications.
Type
- ACE Inhibitors
- Angiotensin Receptor Blockers
- Beta Blockers
- Diuretics
- Others
Application
- Injection
- Capsule
- Tablets
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
End Users
- Hospitals
- Specialty Centres
- Others
Heart failure drugs Market Regional Analysis/Insights
The Heart failure drugs market is analysed and market size insights and trends are provided by country, type, application, distribution channel, and end usesr as referenced above.
The countries covered in the Heart failure drugs market report is U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa.
North America is expected to dominate the global heart failure drugs market due to the increasing prevalence of heart disease in that region.
Asia-Pacific is the fastest-growing region due to increasing awareness and interest in health and wellness.
The country section of the report also provides individual market impacting factors and domestic regulation changes that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The heart failure drugs market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for heart failure drugs market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2015-2020.
Competitive Landscape and Heart Failure Drugs Market Share Analysis
The heart failure drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the heart failure drugs market are:
- Amgen Inc. (U.S.)
- AstraZeneca (U.K.)
- Bayer AG (Germany)
- Novartis AG (Switzerland)
- Gilead Sciences, Inc (U.S.)
- GlaxoSmithKline plc (U.K.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
- Cardurion Pharmaceuticals (U.S.)
- Cardior Pharmaceuticals (Germany)
- Actelion Pharmaceuticals Ltd (Switzerland)
- Boehringer Ingelheim International GmbH (Germany)
- Bristol-Myers Squibb Company (U.S.)
- CYTOKINETICS, INC. (U.S.)
- Eli Lilly and Company (U.S.)
SKU-